key: cord-0025347-i5ktnok1
authors: Stone, William; Mahamar, Almahamoudou; Sanogo, Koualy; Sinaba, Youssouf; Niambele, Sidi M; Sacko, Adama; Keita, Sekouba; Youssouf, Ahamadou; Diallo, Makonon; Soumare, Harouna M; Kaur, Harparkash; Lanke, Kjerstin; ter Heine, Rob; Bradley, John; Issiaka, Djibrilla; Diawara, Halimatou; Traore, Sekou F; Bousema, Teun; Drakeley, Chris; Dicko, Alassane
title: Pyronaridine–artesunate or dihydroartemisinin–piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial
date: 2022-01-03
journal: Lancet Microbe
DOI: 10.1016/s2666-5247(21)00192-0
sha: e3763eb3cb7bfe7fb4c94b6d42657a1b245a4e15
doc_id: 25347
cord_uid: i5ktnok1

BACKGROUND: Pyronaridine–artesunate is the most recently licensed artemisinin-based combination therapy. WHO has recommended that a single low dose of primaquine could be added to artemisinin-based combination therapies to reduce Plasmodium falciparum transmission in areas aiming for elimination of malaria or areas facing artemisinin resistance. We aimed to determine the efficacy of pyronaridine–artesunate and dihydroartemisinin–piperaquine with and without single low-dose primaquine for reducing gametocyte density and transmission to mosquitoes. METHODS: We conducted a four-arm, single-blind, phase 2/3, randomised trial at the Ouélessébougou Clinical Research Unit of the Malaria Research and Training Centre of the University of Bamako (Bamako, Mali). Participants were aged 5–50 years, with asymptomatic P falciparum malaria mono-infection and gametocyte carriage on microscopy, haemoglobin density of 9·5 g/dL or higher, bodyweight less than 80 kg, and no use of antimalarial drugs over the past week. Participants were randomly assigned (1:1:1:1) to one of four treatment groups: pyronaridine–artesunate, pyronaridine–artesunate plus primaquine, dihydroartemisinin–piperaquine, or dihydroartemisinin–piperaquine plus primaquine. Treatment allocation was concealed to all study staff other than the trial pharmacist and treating physician. Dihydroartemisinin–piperaquine and pyronaridine–artesunate were administered as per manufacturer guidelines over 3 days; primaquine was administered as a single dose in oral solution according to bodyweight (0·25 mg/kg; in 1 kg bands). The primary endpoint was percentage reduction in mosquito infection rate (percentage of mosquitoes surviving to dissection that were infected with P falciparum) at 48 h after treatment compared with baseline (before treatment) in all treatment groups. Data were analysed per protocol. This trial is now complete, and is registered with ClinicalTrials.gov, NCT04049916. FINDINGS: Between Sept 10 and Nov 19, 2019, 1044 patients were assessed for eligibility and 100 were enrolled and randomly assigned to one of the four treatment groups (n=25 per group). Before treatment, 66 (66%) of 100 participants were infectious to mosquitoes, with a median of 15·8% (IQR 5·4–31·9) of mosquitoes becoming infected. In individuals who were infectious before treatment, the median percentage reduction in mosquito infection rate 48 h after treatment was 100·0% (IQR 100·0 to 100·0) for individuals treated with pyronaridine–artesunate plus primaquine (n=18; p<0·0001) and dihydroartemisinin–piperaquine plus primaquine (n=15; p=0·0001), compared with −8·7% (−54·8 to 93·2) with pyronaridine–artesunate (n=17; p=0·88) and 50·4% (13·8 to 70·9) with dihydroartemisinin–piperaquine (n=16; p=0·13). There were no serious adverse events, and there were no significant differences between treatment groups at any point in the frequency of any adverse events (Fisher's exact test p=0·96) or adverse events related to study drugs (p=0·64). The most common adverse events were headaches (40 events in 32 [32%] of 100 participants), rhinitis (31 events in 30 [30%]), and respiratory infection (20 events in 20 [20%]). INTERPRETATION: These data support the use of single low-dose primaquine as an effective supplement to dihydroartemisinin–piperaquine and pyronaridine–artesunate for blocking P falciparum transmission. The new pyronaridine–artesunate plus single low-dose primaquine combination is of immediate relevance to regions in which the containment of partial artemisinin and partner-drug resistance is a growing concern and in regions aiming to eliminate malaria. FUNDING: The Bill & Melinda Gates Foundation. TRANSLATIONS: For the French, Spanish and Swahilil translations of the abstract see Supplementary Materials section.

Participants in the DP or DP-PQ arm were treated with standard doses of DP. DP treatment Tablets containing 160/320 mg piperaquine w. 20/40 mg dihydroartemisinin tablets (Eurartesim, Sigma Tau) were administered according to weight as per manufacturer guidelines shown below: Participants in the DP and PA arms received a full course of DP at baseline and a second full course at day 21, to ensure prophylaxis for the duration of follow-up.

Participants in the PA or PA-PQ arm were treated with standard doses of PA. PA granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.) were administered to children <20kg, and PA tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate were administered to children and adults >20kg, according to weight as per manufacturer guidelines shown below:

Granules (Children <20kg)

Total daily dose (mg) (1x/day for 3 days)

The primary endpoint of the current trial is the median within person percent reduction in mosquito infection rate (the percentage of mosquitoes surviving to dissection that each participant infected) at day 2 compared to baseline. Sample size was informed by previous trials (2, 3) . In those studies, ~79% of individuals infected at least one mosquito before treatment, and among those who infected at least one mosquito, an average of 24% of mosquitoes became infected, giving an estimated probability of mosquito infection of 0·79 × 0·24 = 0·190. Using a standard deviation of 0·24 for the change in proportion of infected mosquitoes before and after treatment (estimated from the same data), with 25 participants per arm, we would have 80% power to detect a 95% or greater reduction in infectivity (from 0·190 to 0·009) as statistically significant at the 0.05 level. With 25 participants per group, we would have 80% power to detect an 80% or greater reduction in the proportion of infectious individuals after treatment (a secondary outcome) as significant at the 0.05 level. Sample sizes were designed to assess reduction in mosquito infectivity over time within arms, not between arms. A formal comparison between arms would have necessitated larger sample sizes that affect the logistic feasibility of the study by the need to find sufficient gametocyte carriers in a single transmission season, and the required logistical intensity of mosquito membrane feeding assays (in terms of mosquito husbandry and labour). As in previous studies, we included between arm comparisons as secondary outcomes and report these data. 

Day 35 DP 0 (0/23) nc 0 (0/5) nc PA 0 (0/22) nc 0 (0/2) nc Day 42 DP 0 (0/23) nc 0 (0/1) nc PA 0 (0/22) nc 0 (0/1) nc

i

Day of follow-up Treatment arm Gametocyte circulation time was calculated using a deterministic compartmental model (4), and is presented as the model estimate (mean days) with 95% CI. Area under the curve (AUC) of gametocyte density per participant over time was calculated using the linear trapezoid method (5), and is presented as the median and IQR of individual AUC values by treatment arm. P-values are for differences in the t-statistic between ACT matched treatment groups. Ref = reference group. Circulation time and AUC were calculated using the first 28 days of observation only. 

P-values are for differences between ACT matched treatment groups. Density and proportion male were compared using Wilcoxon rank sum tests, and prevalence was compared using Fishers exact tests. For males and females, Proportion male is given for participants/timepoints with total gametocyte densities of 0.2/µL and over, as described previously (3). For the calculation of gametocyte prevalence, samples were classified as negative for a particular gametocyte sex if the estimated density of in gametocytes of that sex was less than 0·01/μL (i.e. one gametocyte per 100 μL of blood sample). nc = not calculable, no observations/no observations over the threshold density for analysis. -= not tested. ref = reference group. P-values are for differences between ACT matched treatment groups. Density was compared using Wilcoxon rank sum tests, and prevalence was compared using Fishers exact tests. For the calculation of gametocyte prevalence, samples were classified as negative for a particular gametocyte sex if the estimated density of in gametocytes of that sex was less than 0·01 gametocytes per μL (i.e. one gametocyte per 100 μL of blood sample). Absolute haemoglobin density and percent change in haemoglobin density (relative to baseline) were compared within treatment arms using paired t-tests (with day 0 as reference for percent change) (p-value ¥ ), and between treatment arms using two-way t-tests (p-value † ). P-values are from Fisher's exact tests for differences in proportion of individuals with an AE between all groups* or between ACT matched treatment arms**. Classification as 'related to treatment' was defined as probably, possibly or definitely related to treatment, as described in the methods.

P-values (<0.05) for differences between ACT matched treatment groups were calculated using Wilcoxon rank sum tests and are

Supplementary figure 3. Percent change in haemoglobin density

Box plots represent median within person percent change from baseline in each treatment arm. P-values (<0.05) from paired T-tests of the difference in mean percent change between time-points within each treatment arm are indicated with asterisks (*). Outliers were excluded from these plots to allow standardisation of axes

Absolute haemoglobin density is given in grams per dL (y axis, from 8-20g/dL) and is indicated for each participant individually with grey lines. The single black line shows the mean absolute haemoglobin density. P-values (<0.05) from paired t-tests for the difference in mean haemoglobin density relative to baseline

A multiplex assay for the sensitive detection and quantification of male and female Plasmodium falciparum gametocytes

Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, doseranging, adaptive randomised phase 2 trial

Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial

Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs

Use of area under the curve to characterize transmission potential after antimalarial treatment